Pulmonary vein narrowing after pulsed field versus thermal ablation.

"Conflict of interest: M.M. is a consultant for Boston Scientific, Biosense Webster, Abbott, Medtronic, Siemens Novartis, Janssen, Boehringer Ingelheim, Pfizer, and SentreHEART/AtriCure and has equity in EPD-Philips (divested), and NewPace Ltd. E.P.G. is a consultant to Farapulse Inc and serves as an unpaid consultant to Boston Scientific Inc and scientific advisory board to Biosense Webster and Adagio Medical, has research support from Biosense-Webster, Adagio Medical, and Abbott, has lecture honoraria from Medtronic, Boston Scientific Inc and Abbott. C.P. is a consultant for Boston Scientific. A.N. is a consultant for Abbott, Baylis, Biotronik, Biosense Webster, Boston Scientific, and Medtronic. W.W. has no relevant disclosures. F.A.C. is a consultant to Boston Scientific and Biosense Webster. S.E.M. is a consultant to Medtronic and Boston Scientific Inc, has research support from Medtronic, Biotronik, Abbott, and CVRx, and has lecture honoraria from Biosense Webster, Medtronic, Boston Scientific Inc, Zoll, and Abbott. D.N.G. is a consultant to Abbott, Baylis, Biotronik, Biosense Webster, Boston Scientific, and Medtronic. J.D.H. has no relevant disclosures. S.K.H. is an employee of Medpace Core Laboratories. C.W.S., A.B.A., E.M.A., and K.M.S. are employees of Boston Scientific. A.S.M. is a consultant to Farapulse Inc and serves as a consultant to Boston Scientific Inc; unrelated to this manuscript, he has also provided statistical consulting and/or Data Safety Monitoring Board services for AtriCure, Abbott, Biosense Webster, and Medtronic. J.W.L. is a consultant to and received equity from Farapulse Inc (now divested) and serves as a consultant to Boston Scientific Inc. V.Y.R. is a Farapulse-Boston Scientific Inc: grant support, consultant, equity (now divested); and unrelated to this manuscript, V.Y.R. also serves as a consultant for and has equity in Ablacon, Acutus Medical, Affera-Medtronic, Apama Medical-Boston Scientific, Anumana, APN Health, AquaHeart, AtaCor, Autonomix, Axon Therapies, Backbeat, BioSig, CardiaCare, CardioNXT/AFTx, Circa Scientific, CoRISMA, Corvia Medical, Dinova-Hangzhou DiNovA EP Technology, East End Medical, EPD-Philips, EP Frontiers, Epix Therapeutics-Medtronic, EpiEP, Eximo, Field Medical, Focused Therapeutics, HRT, Intershunt, Javelin, Kardium, Keystone Heart, LuxMed, MedLumics, Middlepeak, NeuTrace, Nuvera-Biosense Webster, Oracle Health, Restore Medical, Sirona Medical, SoundCath, Valcare; unrelated to this work, V.Y.R. has served as a consultant for Abbott, AtriAN, Biosense Webster, BioTel Heart, Biotronik, Cairdac, CardioFocus, Cardionomic, CoreMap, Fire1, Gore & Associates, Impulse Dynamics, Medtronic, Novartis, Philips, and Pulse Biosciences and has equity in DRS Vascular, Manual Surgical Sciences, NewPace, Nyra Medical, SureCor, and VizaraMed."

"Funding The ADVENT study was funded by Boston Scientific."